Deutsche Bank Downgrades Evotec to Hold
Deutsche Bank analyst Falko Friedrichs downgrades Evotec (NASDAQ:EVO) from Buy to Hold.
HC Wainwright & Co. Downgrades Neoleukin Therapeutics to Neutral
HC Wainwright & Co. analyst Robert Burns downgrades Neoleukin Therapeutics (NASDAQ:NLTX) from Buy to Neutral.
Wolfe Research Downgrades Magellan Midstream to Underperform, Announces $49 Price Target
Wolfe Research analyst Keith Stanley downgrades Magellan Midstream (NYSE:MMP) from Peer Perform to Underperform and announces $49 price target.
UBS Downgrades Corteva to Neutral, Raises Price Target to $73
UBS analyst Joshua Spector downgrades Corteva (NYSE:CTVA) from Buy to Neutral and raises the price target from $70 to $73.
Keybanc Downgrades Rapid7 to Sector Weight
Keybanc analyst Michael Turits downgrades Rapid7 (NASDAQ:RPD) from Overweight to Sector Weight.
TD Securities Downgrades Shawcor to Hold, Raises Price Target to C$13
TD Securities analyst Aaron Macneil downgrades Shawcor (TSX:SCL) from Buy to Hold and raises the price target from C$12 to C$13.
Jefferies Downgrades GAN to Hold, Announces $2 Price Target
Jefferies analyst David Katz downgrades GAN (NASDAQ:GAN) from Buy to Hold and announces $2 price target.
Jefferies Downgrades Lumos Pharma to Hold, Announces $7 Price Target
Jefferies analyst Eun Yang downgrades Lumos Pharma (NASDAQ:LUMO) from Buy to Hold and announces $7 price target.
Ladenburg Thalmann Downgrades Calithera Biosciences to Neutral
Ladenburg Thalmann analyst Aydin Huseynov downgrades Calithera Biosciences (NASDAQ:CALA) from Buy to Neutral.
Wedbush Downgrades Impel Pharmaceuticals to Neutral, Lowers Price Target to $5
Wedbush analyst Laura Chico downgrades Impel Pharmaceuticals (NASDAQ:IMPL) from Outperform to Neutral and lowers the price target from $24 to $5.